WO2005015205A3 - Utilisation de sap - Google Patents

Utilisation de sap Download PDF

Info

Publication number
WO2005015205A3
WO2005015205A3 PCT/EP2004/008824 EP2004008824W WO2005015205A3 WO 2005015205 A3 WO2005015205 A3 WO 2005015205A3 EP 2004008824 W EP2004008824 W EP 2004008824W WO 2005015205 A3 WO2005015205 A3 WO 2005015205A3
Authority
WO
WIPO (PCT)
Prior art keywords
sap
slam
phosphatase
assays
associated protein
Prior art date
Application number
PCT/EP2004/008824
Other languages
English (en)
Other versions
WO2005015205A2 (fr
Inventor
Tamas Schweighoffer
Erwin Paul Schreiner
Original Assignee
Novartis Ag
Novartis Pharma Gmbh
Tamas Schweighoffer
Erwin Paul Schreiner
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag, Novartis Pharma Gmbh, Tamas Schweighoffer, Erwin Paul Schreiner filed Critical Novartis Ag
Publication of WO2005015205A2 publication Critical patent/WO2005015205A2/fr
Publication of WO2005015205A3 publication Critical patent/WO2005015205A3/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/42—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving phosphatase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/03—Phosphoric monoester hydrolases (3.1.3)
    • C12Y301/03001—Alkaline phosphatase (3.1.3.1)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne l'utilisation d'une SLAM (molécule d'activation lymphocytaire de signalisation) associée à une protéine (SAP) agissant comme une phosphatase et dans des dosages.
PCT/EP2004/008824 2003-08-08 2004-08-06 Utilisation de sap WO2005015205A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49383103P 2003-08-08 2003-08-08
US60/493,831 2003-08-08

Publications (2)

Publication Number Publication Date
WO2005015205A2 WO2005015205A2 (fr) 2005-02-17
WO2005015205A3 true WO2005015205A3 (fr) 2005-06-23

Family

ID=34135289

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2004/008824 WO2005015205A2 (fr) 2003-08-08 2004-08-06 Utilisation de sap

Country Status (1)

Country Link
WO (1) WO2005015205A2 (fr)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999026980A1 (fr) * 1997-11-21 1999-06-03 Beth Israel Deaconess Medical Center Reactifs et procedes d'utilisation de proteines de la famille sap, nouveaux regulateurs de transduction de signaux
WO2000058350A1 (fr) * 1999-03-26 2000-10-05 Human Genome Sciences, Inc. 49 proteines secretees par un etre humain

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999026980A1 (fr) * 1997-11-21 1999-06-03 Beth Israel Deaconess Medical Center Reactifs et procedes d'utilisation de proteines de la famille sap, nouveaux regulateurs de transduction de signaux
WO2000058350A1 (fr) * 1999-03-26 2000-10-05 Human Genome Sciences, Inc. 49 proteines secretees par un etre humain

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
CASTRO A G ET AL: "Molecular and functional characterization of mouse signaling lymphocytic activation molecule (SLAM): differential expression and responsiveness in Th1 and Th2 cells.", JOURNAL OF IMMUNOLOGY (BALTIMORE, MD. : 1950) 1 DEC 1999, vol. 163, no. 11, 1 December 1999 (1999-12-01), pages 5860 - 5870, XP001206085, ISSN: 0022-1767 *
GILMOUR KIMBERLY C ET AL: "Diagnosis of X-linked lymphoproliferative disease by analysis of SLAM-associated protein expression", EUROPEAN JOURNAL OF IMMUNOLOGY, vol. 30, no. 6, June 2000 (2000-06-01), pages 1691 - 1697, XP001206214, ISSN: 0014-2980 *
MACGINNITIE ANDREW J ET AL: "X-linked lymphoproliferative disease: genetic lesions and clinical consequences.", CURRENT ALLERGY AND ASTHMA REPORTS. SEP 2002, vol. 2, no. 5, September 2002 (2002-09-01), pages 361 - 367, XP009046726, ISSN: 1529-7322 *
MORRA MASSIMO ET AL: "Structural basis for the interaction of the free SH2 domain EAT-2 with SLAM receptors in hematopoietic cells", EMBO (EUROPEAN MOLECULAR BIOLOGY ORGANIZATION) JOURNAL, vol. 20, no. 21, 1 November 2001 (2001-11-01), pages 5840 - 5852, XP002325721, ISSN: 0261-4189 *
NICHOLS KIM E ET AL: "Inactivating mutations in an SH2 domain-encoding gene in X-linked lymphoproliferative syndrome", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 95, no. 23, 10 November 1998 (1998-11-10), pages 13765 - 13770, XP002325722, ISSN: 0027-8424 *
NISTALA K ET AL: "X-linked lymphoproliferative disease: Three atypical cases", CLINICAL AND EXPERIMENTAL IMMUNOLOGY, vol. 126, no. 1, October 2001 (2001-10-01), pages 126 - 130, XP001206234, ISSN: 0009-9104 *

Also Published As

Publication number Publication date
WO2005015205A2 (fr) 2005-02-17

Similar Documents

Publication Publication Date Title
WO2006017274A3 (fr) Systemes et procedes pour modification d'echantillons au moyen de chambres fluidiques
WO2003072803A3 (fr) Nanostructures contenant des unites d'assemblage d'anticorps
AU2003284055A1 (en) Microfluidic systems and components
AU2003271186A1 (en) Double specific antibodies substituting for functional protein
AU2003243736A1 (en) Improved assay systems and components
AU2003297214A1 (en) Microfluidic system with integrated permeable membrane
IL212752A0 (en) An molecule directed against the ??-secretase cleavage site of amyloid precursor protein, and uses thereof
AU2003271839A1 (en) Dart-operated big bore by-pass valve
IL173843A0 (en) Assay for coronaviruses, reagents for use therein and kits containing the same
AU2003286640A1 (en) Biological fluid filter
AU2003265759A1 (en) Fluid drain assembly
NL1024616A1 (nl) Depotpreparaten in de vorm van een suspensie.
WO2004003149A8 (fr) Polypeptides cngh0005, anticorps, compositions, methodes et utilisations
AU2003233136A1 (en) Disazo dyes having adapted affinity
AU2002950611A0 (en) Blood flow analysis system
AU2003285385A1 (en) The transmembrane protein amigo and uses thereof
EP1576115A3 (fr) Puces de proteines
WO2005015205A3 (fr) Utilisation de sap
TWI350890B (en) Valve and fluid system having the same
AU2003272169A1 (en) Assay with co-immobilized ligands
AU2003249533A1 (en) Neoplasm specific antibodies and uses thereof
WO2003091447A3 (fr) Acides nucleiques d1-1, polypeptides et methodes associees
AU2003260606A1 (en) Bistable membrane valve
AU2003299106A1 (en) Metering pump and valve assembly for use in the same
AU2003252383A1 (en) Test piece for protein assay and process for producing the same

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase